Reversible synaptic deficits in early-stage batten disease

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Juvenile neuronal ceroid lipofuscinosis (JNCL), also known as Batten Disease, is a childhood neurodegenerative disorder.
• It stems from mutations in the CLN3 gene, leading to progressive cognitive decline.
• Current treatments are limited, and the neuronal function of CLN3 remains unclear.

Purpose of the Study:

• To investigate the role of CLN3 in neuronal function and synaptic plasticity.
• To explore the pathomechanisms underlying cognitive impairment in JNCL.
• To assess the potential of gene therapy for treating JNCL.

Main Methods:

• Electrophysiological recordings (patch clamp, microelectrode arrays) in Cln3-deficient mouse models.
• Confocal imaging to quantify dendritic spine density.
• Adeno-associated virus (AAV)-mediated gene re-expression of CLN3 combined with optogenetics.

Main Results:

• Loss of CLN3 impairs synaptic vesicle release and reduces synaptic strength.
• Deficits in intrinsic neuronal excitability and network activity were observed.
• CLN3 is essential at both pre- and postsynaptic sites for neuronal function.
• AAV9-mediated gene therapy restored synaptic function in early-stage Cln3-deficient mice.

Conclusions:

• CLN3 is critical for maintaining synaptic integrity and function.
• Gene therapy can reverse established synaptic deficits in JNCL models.
• The therapeutic window for JNCL may extend to stages with functional impairments.
• Early synaptic deficits serve as valuable readouts for preclinical research.